NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...

The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...

Considering taking supplements to treat macular telangiectasia type 2? Below is a list of common natural remedies used to treat or reduce the symptoms of macular telangiectasia type 2. Follow the ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

In the long term, dermal atrophy and/or induration are expected. Radiation induced telangiectasia and skin weakness are also probable. Skin reactions that may be observed in this dose range belong to ...

GTx-102 is a novel, concentrated oral-mucosal spray of betamethasone intended to improve neurological symptoms of Ataxia-Telangiectasia (A-T), for which there are currently no FDA-approved therapies.

Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ...

GRCE READ THE FULL GRCE RESEARCH REPORT We are initiating coverage of Grace Therapeutics, Inc. (NASDAQ:GRCE) with a valuation of $12.50 per share. This value is based on our estimates for the ...